Welcome to our dedicated page for Agilent Technologies SEC filings (Ticker: A), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Agilent Technologies Inc. filings document financial reporting and governance matters for an analytical and clinical laboratory technology company. Form 8-K reports include quarterly financial-result releases, Regulation FD disclosures, non-GAAP measure explanations, executive officer transitions, compensatory arrangements and amendments to charter and bylaws.
Proxy and annual-meeting filings cover director elections, stockholder voting, executive compensation, equity awards and the phased declassification of the board. The records also identify governance changes tied to the company’s Delaware certificate of incorporation and bylaws, together with furnished press releases and related exhibits.
Agilent Technologies (A) insider transaction: The company’s President and CEO, also a director, exercised 12,490 stock options at $109.86 per share on 11/12/2025 and sold 12,490 common shares at $150 the same day. Following these transactions, the reporting person directly owned 33,448 shares.
The activity was conducted under a Rule 10b5-1 plan adopted on March 28, 2025. The options were granted under the 2018 Stock Plan, originally awarded on November 17, 2020, and became exercisable in four equal annual installments beginning one year after grant, with an expiration date of November 17, 2030.
A filed a Form 144 reporting a proposed sale of 12,490 shares of common stock with an aggregate market value of $1,873,500. The planned transaction lists Fidelity Brokerage Services LLC as broker and the NYSE as the exchange, with an approximate sale date of 11/12/2025.
The shares were acquired on 11/12/2025 from the issuer via an option granted on 11/17/2020, with cash payment. Over the past three months, Padraig Mcdonnell sold 2,000 shares on 09/02/2025 for gross proceeds of $249,760.
Agilent Technologies appointed Adam S. Elinoff as Senior Vice President and Chief Financial Officer, effective November 17, 2025, replacing interim CFO Rodney Gonsalves, who continues as Vice President, Corporate Controller and Principal Accounting Officer.
The compensation package includes a base salary of $700,000 and eligibility for an annual bonus targeted at 80% of base salary. Equity awards comprise fiscal 2025 RSUs with a target value of $1,100,000 and performance-based RSUs for the fiscal 2026–2028 period with a target value of $1,650,000, effective November 18, 2025. The Committee also approved a one-time cash bonus of $800,000 subject to repayment if employment ends within 12 months, plus sign-on RSUs targeted at $560,000 and performance-based RSUs targeted at $840,000.
RSUs vest over four years. Performance-based RSUs vest on October 31, 2028 with payout ranging from 0% to 200% based on Company performance. Agilent furnished a press release as Exhibit 99.1.
Form 144 notice for Agilent Technologies Inc. (symbol: A) reports a proposed sale of 5,781 common shares through Fidelity Brokerage Services on 09/09/2025 with an aggregate market value of $729,591.11. The shares were acquired on 11/15/2022 upon restricted stock vesting and were issued as compensation. The filing also discloses prior sales by Robert W. McMahon of 28,081 shares on 08/29/2025 for $3,508,994.14 and 15,303 shares on 09/04/2025 for $1,968,223.83. The total shares outstanding reported in the form are 283,500,427. Several administrative fields such as filer CIK and issuer address are not provided in the text.
Form 144 notice for Agilent Technologies, Inc. (A) discloses a proposed sale of 15,303 common shares through Fidelity Brokerage Services (NYSE) with an aggregate market value of $1,968,223.83, and records prior sales by the same person. The shares to be sold were acquired as restricted stock that vested in November 2021 in four tranches (1,899; 10,935; 689; 1,780). The filing lists a prior sale by Robert W. McMahon of 28,081 shares on 08/29/2025 for gross proceeds of $3,508,994.14. The notice includes the seller's certification that they are not aware of undisclosed material adverse information about the issuer.
Padraig McDonnell, who is listed as President and CEO and a Director of Agilent Technologies (A), reported a sale of 2,000 shares of Agilent common stock on 09/02/2025 at a reported price of $124.88 per share. After the transaction McDonnell beneficially owned 33,448 shares. The filing notes the sale was executed pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 28, 2025. The Form 4 was signed by an attorney-in-fact on behalf of Mr. McDonnell and filed on 09/04/2025.
Form 144 filing for Agilent Technologies, Inc. (A): The filer notified an intended sale of 2,000 shares of common stock through Fidelity Brokerage Services with an aggregate market value of $249,760.00, with an approximate sale date of 09/02/2025 on the NYSE. The schedule lists the acquisition of smaller blocks of restricted stock that vested between 11/14/2023 and 05/19/2024 (totaling 2,000 shares listed). The filing also discloses two prior sales by the same person in 07/2025 (1,508 shares) and 08/2025 (2,000 shares) with gross proceeds shown.
Agilent Technologies (A) reported condensed, unaudited quarterly results for the three and nine months ended July 31, 2025, prepared under U.S. GAAP and recast to reflect a new three-segment structure: Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets.
Services and other revenue grew 11% for the quarter and 9% year-to-date, driven by contract repair, preventative maintenance and on-demand services. Income from operations rose $4 million (3%) for the quarter and $21 million (6%) year-to-date on revenue increases, while operating margins faced near-term pressure from increased tariffs, shipping costs, unfavorable mix, warranty and variable pay. No goodwill impairment was indicated after quantitative testing. The company repurchased shares under its repurchase programs and paid quarterly dividends; commercial paper outstanding was $55 million at a 4.55% weighted average rate.
Agilent Technologies (A) Form 144 notice shows a proposed sale of 28,081 common shares via Fidelity Brokerage Services on the NYSE with an aggregate market value of $3,508,993.30. The filing lists two option-originated lots: 22,898 shares from an option granted 11/17/2020 and 5,183 shares from an option granted 11/22/2023, both indicated as to be sold on 08/29/2025 for cash. The filer reports 284,064,728 shares outstanding and no sales by the same person in the past three months. The notice contains the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Agilent Technologies Inc. (A) Form 144 shows a proposed sale of 21,644 common shares through Fidelity Brokerage Services with an aggregate market value of $2,706,365.76. The shares represent a small fraction of the 284,064,728 shares outstanding and the approximate sale date is 08/29/2025 on the NYSE. The shares to be sold were acquired upon option exercises dated 11/17/2020, 05/03/2022, and 11/22/2023, and payment is indicated as cash. The filer states there are no undisclosed material adverse facts and reports no securities sold in the past three months.